Trmt2a Inhibitors for Use in the Treatment of Polyglutamine Diseases

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent describes the use of inhibitors targeting the enzyme TRMT2A to treat or prevent polyglutamine (polyQ) diseases, such as Huntington's disease and various spinocerebellar ataxias. The invention identifies specific chemical compounds that inhibit TRMT2A, showing that this inhibition reduces toxic protein aggregation in cells, which is a main hallmark of polyQ neurodegenerative disorders. The invention encompasses pharmaceutical compositions and enriched food products containing these inhibitors for therapeutic or preventive use.

Use CasesContent extracted from patent full text and abstract with AI.

• Treatment of Huntington's disease in symptomatic patients to reduce severity or progression of symptoms.
• Preventive treatment in individuals genetically predisposed to polyglutamine diseases, delaying disease onset or progression.
• Therapeutic intervention for other polyQ disorders, such as spinocerebellar ataxias (SCA), dentatorubral pallidoluysian atrophy (DRPLA), and spinal and bulbar muscular atrophy (SBMA).
• Combination therapies with existing neurodegenerative disease drugs (e.g., Tetrabenazine) for improved outcomes.
• Inclusion of TRMT2A inhibitors in functional foods or dietary supplements for at-risk populations.
• In vitro research tools for studying polyglutamine aggregation and toxicity.

BenefitsContent extracted from patent full text and abstract with AI.

• Provides a novel therapeutic approach for currently incurable polyglutamine diseases, potentially affecting a large patient population.
• Effective in both prevention and treatment, targeting both pre-symptomatic and symptomatic individuals.
• Reduces pathological protein aggregation, which is directly linked to neuronal cell death and symptom severity in polyQ diseases.
• Potential for oral or other non-invasive administration, improving patient compliance over existing therapies requiring more invasive methods.
• Chemical inhibition of TRMT2A demonstrated as safe in model organisms, with minimal effect on normal viability, suggesting a favorable safety profile.
• Possibility of using naturally occurring nutrients or micronutrients as mild TRMT2A inhibitors, allowing development of preventive foods or supplements.
• Can be incorporated into multi-drug regimens, potentially increasing treatment efficacy.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The present invention relates to inhibitors of the enzyme TRMT2A and medical uses thereof. More particularly, the present invention relates to the treatment and the prevention of polyglutamine diseases using TRMT2A inhibitors.